I now have comprehensive data from multiple authoritative sources. Let me compile the full answer.
Headache Management
A structured, evidence-based overview covering classification, acute treatment, prophylaxis, and special headache types.
1. Classification - Red Flags First
Before managing headache, exclude secondary (dangerous) causes. The key warning signs are:
- "Thunderclap" - sudden, worst-ever headache (subarachnoid hemorrhage until proven otherwise)
- New headache in age >50 (giant cell arteritis, mass lesion)
- Fever + neck stiffness (meningitis)
- Headache with focal neurologic signs or papilloedema
- Progressive worsening over days/weeks
- Headache in a cancer or immunocompromised patient
90% of patients presenting to primary care with headache have migraine. - Harrison's Principles of Internal Medicine 22E, 2025
2. Primary Headache Types & Their Management
A. Migraine
Acute (Abortive) Treatment
Step up based on attack severity:
Step 1 - Mild attacks:
- Aspirin, acetaminophen, or NSAIDs (ibuprofen, naproxen)
- Combination: acetaminophen + aspirin + caffeine (FDA-approved)
- Add a dopamine antagonist (metoclopramide 10 mg, prochlorperazine 10 mg) if nausea is present - also enhances GI absorption
Step 2 - Moderate-to-severe attacks (after NSAID failure):
| Drug | Route | Dose |
|---|
| Sumatriptan | PO | 50-100 mg |
| Rizatriptan | PO | 10 mg |
| Eletriptan | PO | 40 mg |
| Almotriptan | PO | 12.5 mg |
| Zolmitriptan | PO/nasal | 2.5 mg / 5 mg nasal |
| Sumatriptan | SC | 6 mg (fastest onset) |
| Sumatriptan | Nasal | 20 mg |
| Rimegepant (CGRP antagonist) | PO | 75 mg |
| Ubrogepant (CGRP antagonist) | PO | 50-100 mg |
| Lasmiditan (5-HT1F agonist) | PO | 50-200 mg |
Triptans are selective 5-HT1B/1D receptor agonists. Rizatriptan and eletriptan are the most efficacious on a population basis. Sumatriptan and zolmitriptan offer multiple formulations. - Harrison's
Triptan timing is key: Give oral/nasal forms at aura onset; SC at headache onset. Do NOT give during aura to prevent headache - they are ineffective in the aura phase but safe if given then.
Triptan contraindications: Ischemic heart disease, uncontrolled hypertension, basilar or hemiplegic migraine, concurrent MAOIs.
Special clinical situations (from Harrison's treatment table):
| Situation | Preferred Option |
|---|
| Early vomiting | Zolmitriptan 5 mg nasal / Sumatriptan 6 mg SC |
| Rapid onset headache | SC or nasal triptans / DHE IM |
| Headache recurrence | Ergotamine 2 mg PR / Naratriptan 2.5 mg / Eletriptan 40 mg |
| Poor tolerance of acute therapy | Naratriptan, Almotriptan, Rimegepant, neuromodulation |
| Menstrual migraine prevention | Frovatriptan, Rimegepant, or estrogen patches during menses |
Dihydroergotamine (DHE): 1 mg IV (over 3 min) or IM, or 2 mg nasal spray. Pretreat with antiemetic. Contraindicated in pregnancy, ischemic heart disease, within 24h of triptan use.
ED/Parenteral setting:
- IV prochlorperazine 5-10 mg (superior to opioids in RCTs)
- IV metoclopramide 10 mg
- IV ketorolac 15-30 mg
- IV mixture: prochlorperazine 5 mg + DHE 0.5 mg over 2 min (common protocol)
- Dexamethasone 6-10 mg IV as adjunct to reduce recurrence
- Magnesium sulfate 2 g IV over 30 min (nonvalidated)
- Opioids: Only for severe infrequent headache unresponsive to other therapies; avoid routine use as they worsen long-term outcomes and decrease future triptan responsiveness
Tintinalli's Emergency Medicine, Table 165-7
Neuromodulation (non-pharmacologic acute options):
- Single-pulse transcranial magnetic stimulation (sTMS) - FDA cleared
- Noninvasive vagus nerve stimulator (nVNS) - FDA cleared
- Remote electrical neuromodulation (arm device)
- Transcutaneous supraorbital nerve stimulation
Migraine Prophylaxis (Preventive Treatment)
Indicated when: ≥4 headache days/month, attacks significantly impairing function, failure/contraindication to acute therapies, medication overuse headache risk, or patient preference.
Established preventive agents:
| Drug Class | Agents | Notes |
|---|
| Beta-blockers | Propranolol, metoprolol, timolol | First-line; avoid in asthma, depression |
| Anticonvulsants | Topiramate, valproate | FDA-approved; valproate teratogenic |
| TCAs | Amitriptyline | Also treats comorbid depression/sleep |
| Calcium channel blockers | Verapamil | More evidence for cluster headache |
| CGRP monoclonal antibodies | Erenumab, fremanezumab, galcanezumab, eptinezumab | New class; SC/IV monthly; very effective |
| CGRP receptor antagonists | Rimegepant (also used acutely) | Oral, twice-weekly for prevention |
| Supplements | Magnesium, riboflavin (B2), CoQ10, feverfew | Modest evidence, good safety |
B. Tension-Type Headache (TTH)
Characteristics: Bilateral, pressing/tightening (non-pulsating), mild-to-moderate, no vomiting, no significant nausea, no aggravation by activity.
Acute treatment:
- Simple analgesics: aspirin, acetaminophen, NSAIDs (first-line for episodic TTH)
- More severe headaches may require prescription analgesics, but no specific preparation has proven superior
- Avoid opioids and barbiturate-containing combinations due to dependence and medication overuse risk
Prevention/chronic TTH:
- Amitriptyline (single bedtime dose) - treatment of choice when anxiety/depression comorbid
- Some evidence for calcium channel blockers, phenelzine, cyproheptadine
- Propranolol and ergotamine are ineffective unless migraine features co-exist
- Biofeedback, relaxation techniques, massage for anxious/stressed patients
- Medication overuse is a key concern - gradual analgesic withdrawal is essential in chronic daily headache
Adams and Victor's Principles of Neurology, 12th Ed.
C. Cluster Headache
Characteristics: Unilateral periorbital/temporal, excruciating (15-180 min), autonomic features (lacrimation, conjunctival injection, nasal congestion, ptosis), episodic or chronic, M > F.
Acute treatment:
- 100% oxygen via mask for 10-15 min at attack onset (highly effective, no side effects)
- Sumatriptan 6 mg SC or zolmitriptan 5 mg nasal spray
- Intranasal lidocaine (adjunct)
- Ergotamine 2 mg orally at bedtime (for predictable nocturnal attacks)
Preventive/transitional treatment:
- Verapamil (up to 480 mg/d) - first-line; requires ECG monitoring in older patients
- Prednisone 75 mg/d tapering over ~3 weeks (short-term bridge)
- Lithium 600-900 mg/d (chronic cluster; monitor for toxicity)
- Galcanezumab (anti-CGRP monoclonal antibody) - halved weekly cluster frequency in clinical trials
- Topiramate, melatonin as alternatives
Adams and Victor's Principles of Neurology, 12th Ed.; Harrison's 22E
D. Trigeminal Autonomic Cephalalgias (TACs) Comparison
| Feature | Cluster | Paroxysmal Hemicrania | SUNCT/SUNA |
|---|
| Duration | 15-180 min | 2-30 min | 5-240 sec |
| Frequency | 1-8/day | 1-20/day | 3-200/day |
| Abortive Rx | O2, sumatriptan SC | Indomethacin (diagnostic) | IV lidocaine |
| Prevention | Verapamil, galcanezumab | Indomethacin | Lamotrigine |
Paroxysmal hemicrania: Complete, absolute response to indomethacin is pathognomonic - start at 25 mg TID, titrate to 75 mg TID.
SUNCT/SUNA: Best prevented with lamotrigine 200-400 mg/d. Topiramate and gabapentin are alternatives.
Hemicrania continua: Unilateral continuous pain + autonomic features; complete response to indomethacin is diagnostic and therapeutic.
E. Medication Overuse Headache (MOH)
- Occurs when acute medications are used >10-15 days/month
- Highest risk: opioids and barbiturates > triptans > NSAIDs
- Treatment: gradual withdrawal of the offending medication (can be done abruptly for triptans/NSAIDs; slower for opioids/barbiturates)
- Preventive therapy should be started during withdrawal
- Multidisciplinary support improves outcomes
3. When to Refer
Per Harrison's 22E: Refer to a headache specialist when:
- No clear diagnosis
- Primary headache other than migraine or TTH
- Unresponsive to two or more standard therapies for the diagnosed type
- Any suspected secondary headache requiring specialist workup
Recent Evidence Note
A 2024
BMJ network meta-analysis (PMID 39293828) on acute migraine management confirmed triptans as effective first-line agents and provided comparative efficacy data across drug classes - consistent with current guideline recommendations.